Brady S, Squier W, Sewry C, *et al.* A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. *BMJ Open* 2014;4:e004552. During the production process some errors to the values in table 2 were inadvertently introduced, specifically to the values in the rows entitled 'MHC class I upregulation' and 'Strong MHC class I upregulation', and columns 'IBM - RV n (%)', 'IBM - RV vs PM&DM Sensitivity' and 'IBM+RV vs IBM - RV p value.' The correct table is provided below.

###### 

Comparison of the proportion of positive cases in each group

  Pathological features                   IBM+RV     PAM       IBM+RV vs PAM   IBM - RV   PM&DM     IBM - RV vs PM&DM   IBM+RV vs IBM - RV          
  --------------------------------------- ---------- --------- --------------- ---------- --------- ------------------- -------------------- ------ --------
  Number of cases                         15 (100)   7 (100)                              9 (100)   11 (100)                                        
  Aggregated proteins, n (%)                                                                                                                        
   p62                                    15 (100)   6 (86)    1.00            0.14       4 (44)    3 (27)\*            0.44                 0.73   0.003†
   TDP-43                                 13 (87)    5 (71)    0.87            0.29       1 (11)    2 (18)\*            0.11                 0.82   0.001†
   Ubiquitin                              11 (73)    4 (57)    0.73            0.43       0 (0)     3 (27)\*            0.00                 0.73   0.001†
   Myotilin                               10 (67)    5 (71)    0.67            0.29       0 (0)     9 (82)              0.00                 0.18   0.002†
   Congophilic deposits                   13 (87)    7 (100)   0.87            0.00       1 (11)    0 (0)               0.11                 1.00   0.001†
  COX−/SDH+ fibres‡, n (%)                                                                                                                          
   Any                                    12 (86)    2 (29)    0.86            0.71       9 (100)   3 (27)              1.00                 0.73   0.50
  Inflammatory features, n (%)                                                                                                                      
   MHC class I upregulation               15 (100)   3 (43)    1.00            0.57       9 (100)   11 (100)            1.00                 0.00   1.00
   Strong MHC class I upregulation        14 (93)    0 (0)     0.93            1.00       7 (78)    10 (91)             0.78                 0.09   0.53
   Partial invasion                       10 (67)    0 (0)     0.67            1.00       3 (33)    2 (18)              0.33                 0.82   0.21
   Endomysial CD3 T-cell score \>1        13 (87)    0 (0)     0.87            1.00       4 (44)    7 (64)              0.44                 0.36   0.06
   Endomysial CD4 T-cell score \>1        12 (80)    0 (0)     0.80            1.00       2 (22)    5 (45)              0.22                 0.54   0.01†
   Endomysial CD8 T-cell score \>0        14 (93)    0 (0)     0.93            1.00       7 (78)    9 (82)              0.78                 0.18   0.53
   Endomysial CD68 macrophage score \>1   12 (80)    0 (0)     0.80            1.00       4 (44)    8 (73)              0.44                 0.27   0.10

\*Pathological features present in DM, but not PM cases.

†Statistically significant results.

‡In IBM with rimmed vacuoles n=14.

COX, cytochrome oxidase; IBM, inclusion body myositis; MHC, major histocompatibility complex; PAM, protein accumulation myopathies with rimmed vacuoles; PM&DM, steroid-responsive inflammatory myopathies; RV, rimmed vacuoles; SDH, succinate dehydrogenase; TDP-43, transactivation response DNA binding protein-43.
